Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

2018 • 3,846 citations

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 • 2,222 citations

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 • 2,104 citations

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 • 1,957 citations

Karnofsky performance status revisited: reliability, validity, and guidelines.

1984 • 1,412 citations

Systemic Therapy for Metastatic Renal-Cell Carcinoma

2017 • 1,066 citations

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

2009 • 480 citations

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

2013 • 426 citations

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

2013 • 390 citations

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 • 326 citations

IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

2018 • 193 citations

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

2018 • 90 citations

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake

2020 • 82 citations

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

2017 • 28 citations

Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer

2020 • 21 citations

Tivozanib in renal cell carcinoma: a new approach to previously treated disease

2020 • 19 citations

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

2020 • 14 citations

Guillain‑Barre syndrome induced by pembrolizumab and sunitinib: A case report

2020 • 12 citations